1. P251 High anti-TNF drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel diseases. (16th January 2018) Authors: Bodini, G; Demarzo, M G; Saracco, M; Coppo, C; Baldissarro, I; Anjali, J; Savarino, E; Savarino, V; Giannini, E Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P252 Low adherence is associated with worse disease course in Ulcerative Colitis: a retrospective study from a single referral center. (21st January 2022) Authors: Viola, A; Demarzo, M G; Abbruzzese, A; Chiappetta, M F; Costantino, G; Alibrandi, A; Fries, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P345 The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease. (21st January 2022) Authors: Macaluso, F S; Grova, M; Saladino, M; Demarzo, M G; Privitera, A C; Giangreco, E; Garufi, S; Renna, S; Casà, A; Ventimiglia, M; Cappello, M; Fries, W; Orlando, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗